MedTrace Logo

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00290628 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-11-29

No results posted yet for this study

Summary

RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This clinical trial is studying how well donor umbilical cord blood transplant works in treating patients with hematologic cancer.

Conditions

Interventions

DRUG

anti-thymocyte globulin

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

filgrastim

DRUG

melphalan

DRUG

methylprednisolone

DRUG

mycophenolate mofetil

PROCEDURE

radiation therapy

PROCEDURE

umbilical cord blood transplantation

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • John E. Wagner, MD · Masonic Cancer Center, University of Minnesota

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290628 on ClinicalTrials.gov